logo
AI Icon𝛼SK or Search
ENTITY

Actuate Therapeutics (ACTU US)

2
Analysis
Health Care • United States
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The company is developing elraglusib, an ATP-competitive small molecule designed to block the function of GSK-3β, which is a master regulator of complex biological signaling cascades that lead to tumor cell survival, growth, migration, and invasion.
more
bearish•Actuate Therapeutics
•09 Oct 2026 15:02

Actuate Therapeutics (ACTU US): Synthetic Expert Call Transcript (09 Oct 2026)

Marginal Clinical Utility in mPDAC: While elraglusib plus gemcitabine/nab-paclitaxel (GnP) demonstrated a statistically significant median...

Logo
Share
bullish•Actuate Therapeutics
•08 Oct 2026 10:04

IPO Databook: Actuate Therapeutics (ACTU US) - Oct 2026

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company developing elraglusib for high impact, difficult to treat cancers by...

Logo
Share
No more insights

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x